What is SLNO's current stock price?

As of now, SLNO is trading at $72.16, with a daily change of -2.05%.

What are SLNO stock strengths?

SLNO strengths include Investors confidence is positive, .

What are the risks associated with SLNO stock?

SLNO Key risk is its Moderate Risk Level, .

What is SLNO next earnings date?

SLNO next earnings report is scheduled for May 7, 2025 .

What is SLNO's current stock rating?

SLNO's current stock rating is Strong Sell.

Should I buy SLNO stock right now?

Based on the current rating of Strong Sell, it is advisable to consider Strong Sell as your next step with SLNO stock.

Is SLNO a Strong Buy right now?

SLNO's current stock rating is Strong Sell, which indicates whether it is a Strong Buy, Buy, Hold, Sell, or Strong Sell.

What does a 'Strong Buy' rating mean for SLNO?

A 'Strong Buy' rating for SLNO indicates that analysts are highly confident in the stock's potential for future growth.

What does a 'Strong Sell' rating mean for SLNO?

A 'Strong Sell' rating for SLNO suggests that analysts anticipate the stock will decline significantly and may not be a good investment.

What factors influence SLNO's stock rating?

SLNO's stock rating is influenced by factors such as market trends, earnings reports, risk factors, and overall sentiment from analysts.

Soleno Therapeutics Inc. (SLNO) Stock Analysis and Insights

LOGIN

Market Overview Trending Stocks Stock Screener Trade Ideas

Top Rated Most Active Strong Potential Positive Momentum Earnings Calendar

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist

SLNO

Soleno Therapeutics Inc.

$72.16

-$1.51 | -2.05%

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

Open

$ 71.38

MKT CAP

$ 3.31B

High

$ 74.00

VOL

$ 921.28K

Low

$ 70.37

AVG VOL

$ 1.56M

Chart

46.13

45.9

54.83

37.9

1year

6month

3month

1month

SLNO Latest Headlines +

PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR. PITTSBURGH March 28 2025 /PRNewswire/ -- PANTHERx® Rare a leader in rare disease product patient access and support services in the United States is pleased to announce that it was selected by Soleno Therapeutics as the specialty pharmacy for the distribution of VYKAT™ XR (diazoxide...

Fri Mar 28, 2025

Activity

Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval.

Thu Mar 27, 2025

Potential

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval Pulling Aardvark Higher. Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease and the biotech stock rocketed.The post Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval Pulling Aardvark Higher appeared first on Investor'.s Business Daily.

Thu Mar 27, 2025

Activity

Momentum

Behind the Scenes of Soleno Therapeuticss Latest Options Trends. Deep-pocketed investors have adopted a bearish approach towards Soleno Therapeutics (NASDAQ:) and it'.s something market players shouldn'.t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown but such a substantial move in SLNO usually suggests something big is about to happen.We gleaned this information from our observations today

Thu Mar 27, 2025

Momentum

Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder. The United States Food and Drug Administration (FDA) on Wednesday approved ) Vykat XR (diazoxide choline) extended-release tablets previously referred to as DCCR for hyperphagia in adults and children 4 years of age and older .Prader-Willi syndrome isa genetic condition characterized by hyperphagia (insatiable hunger) that affects a child’.s .The company says Vykat XR is the first approved ther

Thu Mar 27, 2025

Activity

Soleno Therapeutics Announces United States FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome. First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome

Wed Mar 26, 2025

Activity

Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory.

Fri Mar 21, 2025

Activity

Explore our SLNO Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored SLNO Stock Strategies
Effective Risk Management

FIND US ON

Receive our SLNO Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

Ideas

Earnings

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

SLNO

Soleno Therapeutics Inc.

$72.16

-$1.51 | -2.05%

Chart

46.13

45.9

54.83

37.9

1year

6month

3month

1month

Discover SLNO Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of SLNO. We're here to help you make informed investment decisions today.

FIND US ON

Receive our SLNO Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

SLNO Stock trends

SLNO Stock performance

SLNO Stock analysis

SLNO investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

SLNO Stock Analysis for the Last 90 Days

SLNO Risk Level

SLNO Analysts Opinion

SLNO Street Consensus

SLNO Performance Sentiment

SLNO Financial Health

Explore our SLNO Stock insights

Receive our SLNO Daily Alerts

SLNO Stock Analysis for the Last 90 Days

SLNO Street Consensus

Discover SLNO Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of SLNO. We're here to help you make informed investment decisions today.

Receive our SLNO Daily Alerts